Key Documents

View All Documentation

Fenofibrate Related Compound B

Name: Fenofibrate Related Compound B
Brand: USP

United States Pharmacopeia (USP) Reference Standard

Synonym(s):

2-[4-(4-Chlorobenzoyl)phenoxy]-2-methylpropionic acid, Fenofibric acid

Select a Size

Change View

Pack Size	SKU	Availability	Price

About This Item

Empirical Formula (Hill Notation):

C₁₇H₁₅ClO₄

CAS Number:

42017-89-0

Molecular Weight:

318.75

UNSPSC Code:

41116107

NACRES:

NA.24

PubChem Substance ID:

329749839

MDL number:

MFCD00792461

Beilstein/REAXYS Number:

2058973

Pricing and availability is not currently available.

Technical Service

Need help? Our team of experienced scientists is here for you.

Let Us Assist

Properties

grade

pharmaceutical primary standard

API family

fenofibrate

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

O=C(C1=CC=C(OC(C)(C)C(O)=O)C=C1)C2=CC=C(Cl)C=C2

InChI

1S/C17H15ClO4/c1-17(2,16(20)21)22-14-9-5-12(6-10-14)15(19)11-3-7-13(18)8-4-11/h3-10H,1-2H3,(H,20,21)

InChI key

MQOBSOSZFYZQOK-UHFFFAOYSA-N

Gene Information

human ... PPARA(5465)

Description

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Fenofibrate Related Compound B USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:

Fenofibrate
Fenofibrate Capsules
Fenofibrate Tablets

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.

Disclaimer

Sales restrictions may apply.

Compare Similar Items

View Full Comparison

Show Differences

1 of 1

This Item	1269447	F0048010	PHR2864
USP 1269618 Fenofibrate Related Compound B	USP 1269447 Fenofibrate	F0048010 Fenofibrate impurity B	Supelco PHR2864 Fenofibrate Related Compound A
manufacturer/tradename USP	manufacturer/tradename USP	manufacturer/tradename EDQM	manufacturer/tradename -
grade pharmaceutical primary standard	grade pharmaceutical primary standard	grade pharmaceutical primary standard	grade certified reference material, pharmaceutical secondary standard
format neat	format neat	format neat	format -
application(s) pharmaceutical (small molecule)	application(s) pharmaceutical (small molecule)	application(s) pharmaceutical (small molecule)	application(s) pharmaceutical small molecule
API family fenofibrate	API family fenofibrate	API family fenofibrate	API family fenofibrate
Gene Information human ... PPARA(5465)	Gene Information human ... PPARA(5465)	Gene Information human ... PPARA(5465)	Gene Information -

Still not finding the right product?

Explore all of our products under Fenofibrate Related Compound B

pictograms

GHS07,GHS09

signalword

Warning

hcodes

H302,H410

pcodes

P264 - P270 - P273 - P301 + P312 - P391 - P501

Hazard Classifications

Acute Tox. 4 Oral - Aquatic Acute 1 - Aquatic Chronic 1

Storage Class

11 - Combustible Solids

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

The Lidose hard capsule formulation of fenofibrate is suprabioavailable compared to the nanoparticle tablet formulation under high-fat fed conditions.

Roger K Verbeeck et al.

Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques, 18(1), 61-67 (2015-04-17)

The therapeutic equivalence of multiple registered fenofibrate formulations, several of which are suprabioavailable and therefore marketed at lower dosage strengths than their reference products, is based on the results of bioequivalence studies. Most of these formulations show a higher bioavailability

Endoplasmic reticulum stress involved in high-fat diet and palmitic acid-induced vascular damages and fenofibrate intervention.

Yunxia Lu et al.

Biochemical and biophysical research communications, 458(1), 1-7 (2015-01-17)

Fenofibrate (FF) is widely used to lower blood lipids in clinical practice, but whether its protective effect on endothelium-dependent vasodilatation (EDV) in thoracic aorta is related with endoplasmic reticulum (ER) stress remains unknown. In this study, female Sprauge Dawley rats

Enzymatic characterization of ELOVL1, a key enzyme in very long-chain fatty acid synthesis.

Martin J A Schackmann et al.

Biochimica et biophysica acta, 1851(2), 231-237 (2014-12-17)

X-linked adrenoleukodystrophy (X-ALD) is a neurometabolic disease that is caused by mutations in the ABCD1 gene. ABCD1 protein deficiency impairs peroxisomal very long-chain fatty acid (VLCFA) degradation resulting in increased cytosolic VLCFA-CoA levels, which are further elongated by the VLCFA-specific

Global Trade Item Number

SKU	GTIN
1269618-25MG	04061833850053

Questions

Reviews

No rating value